CPG 10101 combination therapy for the treatment of hepatitis C: a phase II randomized, open label, multi-center, parallel arm, controlled trial of CPG 10101 at two different dose levels with pegylated-interferon-alpha 2B (PEG-IFN) plus ribavirin (RVN) or PEG-IFN plus RVN without CPG 10101 in the treatment of non-responder (null and partial responder) HCV [hepatitis C virus] genotype 1 infected subjects.

Trial Profile

CPG 10101 combination therapy for the treatment of hepatitis C: a phase II randomized, open label, multi-center, parallel arm, controlled trial of CPG 10101 at two different dose levels with pegylated-interferon-alpha 2B (PEG-IFN) plus ribavirin (RVN) or PEG-IFN plus RVN without CPG 10101 in the treatment of non-responder (null and partial responder) HCV [hepatitis C virus] genotype 1 infected subjects.

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Mar 2017

At a glance

  • Drugs CPG 10101 (Primary) ; Peginterferon alfa-2b; Ribavirin
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 07 Jun 2007 The expected completion date for this trial is now 1 Jul 2008.
    • 13 Mar 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top